Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Biologics On FDA Fast Track?: “Follow-On” Process Under Debate

Executive Summary

Data requirements for generic biologics approved under the 505(b)(2) process will be taken up by FDA over the next six months, Center for Drug Evaluation & Research Director Janet Woodcock, MD, said

You may also be interested in...



FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005

FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005

FDA Generic Biologics “Structure” To Come Soon; Policy Debate In 2005

FDA hopes to be in a position to kick off a legislative and policy debate on the feasibility of "follow-on" biologics by the beginning of 2005

Generic Biologics: 505(b)(2) Route Still Open, But Scientific Issues Unresolved

FDA is declining to rule out the possibility that the Sec. 505(b)(2) process could be used to allow expedited approval of follow-on biologic projects

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS041849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel